Early access
Sign in
Taking people in United StatesPhase 3

Daily ASC30 tablet for adults with obesity or overweight

Tests ASC30 tablets against placebo in adults with obesity or overweight.

Key facts

Who runs it
Ascletis Pharma (China) Co., Limited
Where
Austin, Banning, Baton Rouge, Birmingham, Bluffton, Boca Raton, Boise, Bowie, Brownsville, Canton, Charlotte, Chula Vista, Cincinnati, Clemson, Cleveland, Columbia, Columbus, Covina, Dayton, Daytona Beach, Decatur, DeSoto, Eugene, Evansville, Frisco, Gaffney, Gardena, Greenville, Gulfport, Hampton, Huntsville, Indianapolis, Jackson, Jacksonville, Kansas City, La Mesa, Las Vegas, Leesburg, Little Rock, Los Angeles, Melbourne, Memphis, Mesquite, Morehead City, New Windsor, Olive Branch, Philadelphia, Phoenix, Raleigh, Rockville, Salt Lake City, San Antonio, Schaumburg, South Miami, St Louis, Sugar Land, Tampa, Tarzana, The Villages, Tomball, Tucson, Tustin, Union City, Valparaiso, Washington D.C., Weslaco, Wichita Falls, and Winter Park, United StatesSee the 68 sitesAlso in 6 other countries, 37 sites
Trial code
Registry title
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Status
Recruiting
Phase
Phase 3
People taking part
3,003 people, planned
Started
31 Aug 2026
Expected to end
Jul 2028
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ASC30 tablets A1
  • Placebo
Record updated
16 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity, or with overweight and a weight-related health problem, who do not have diabetes.

Age
18 years or older (or the legal age of consent where the study takes place).
Sex
All sexes can join.
Disease stage
BMI 30 kg/m2 or more, or BMI 27 kg/m2 or more with at least 1 weight-related health problem: high blood pressure, abnormal blood fats (dyslipidemia), sleep apnea, or heart and blood vessel disease.
Earlier treatment
At least 1 self-reported unsuccessful attempt to lose weight by diet. Cannot have known allergy or intolerance to other GLP-1 receptor agonist drugs.

Main reasons for not taking part

  • Any diabetes diagnosis (history of gestational diabetes is allowed)
  • Body weight change of more than 5 kg (11 lb) in the 3 months before screening
  • Kidney function eGFR below 15 mL/min/1.73 m2
  • History of acute or chronic pancreatitis
  • Personal or close family history of medullary thyroid carcinoma or MEN syndrome type 2

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Participant must be ≥18 years of age inclusive, or the legal age of consent in the jurisdiction in which the study is taking place at screening
  • Have a BMI ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 and presence of at least 1 of the following weight-related comorbidities (treated or untreated) at screening:; Hypertension; Dyslipidemia; Obstructive sleep apnea; Cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure)
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight

Who cannot take part

  • Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma. Participants with a history of gestational diabetes are eligible to participate in this trial
  • Have a self-reported change in body weight >5 kg (11 pounds) within 3 months prior to screening
  • Have a history of acute or chronic pancreatitis any time prior to screening
  • Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study at the investigator's discretion
  • Have known allergies or intolerance to other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs
  • Participants with a personal or family (first-degree relative) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2
  • Have an estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m2, as determined by the laboratory at screening

Where in United States

Also in 6 other countries, 37 sites

  • Austin, TexasHospital not named in the registryContact: Ascletis RecruitingTaking people
  • Banning, CaliforniaHospital not named in the registryNot yet recruiting
  • Baton Rouge, LouisianaHospital not named in the registryNot yet recruiting
  • Birmingham, AlabamaHospital not named in the registryNot yet recruiting
  • Bluffton, South CarolinaHospital not named in the registryNot yet recruiting
  • Boca Raton, FloridaHospital not named in the registryNot yet recruiting
  • Boise, IdahoHospital not named in the registryNot yet recruiting
  • Bowie, MarylandHospital not named in the registryNot yet recruiting
  • Brownsville, TexasHospital not named in the registryNot yet recruiting
  • Canton, GeorgiaHospital not named in the registryNot yet recruiting
  • Charlotte, North CarolinaHospital not named in the registryNot yet recruiting
  • Chula Vista, CaliforniaHospital not named in the registryNot yet recruiting
  • Cincinnati, OhioHospital not named in the registryNot yet recruiting
  • Clemson, South CarolinaHospital not named in the registryNot yet recruiting
  • Cleveland, OhioHospital not named in the registryNot yet recruiting
  • Columbia, South CarolinaHospital not named in the registryNot yet recruiting
  • Columbus, OhioHospital not named in the registryNot yet recruiting
  • Covina, CaliforniaHospital not named in the registryNot yet recruiting
  • Dayton, OhioHospital not named in the registryNot yet recruiting
  • Daytona Beach, FloridaHospital not named in the registryNot yet recruiting
  • Decatur, GeorgiaHospital not named in the registryNot yet recruiting
  • DeSoto, TexasHospital not named in the registryNot yet recruiting
  • Eugene, OregonHospital not named in the registryNot yet recruiting
  • Evansville, IndianaHospital not named in the registryContact: Ascletis RecruitingTaking people
  • Frisco, TexasHospital not named in the registryNot yet recruiting
  • Gaffney, South CarolinaHospital not named in the registryNot yet recruiting
  • Gardena, CaliforniaHospital not named in the registryNot yet recruiting
  • Greenville, North CarolinaHospital not named in the registryNot yet recruiting
  • Gulfport, MississippiHospital not named in the registryNot yet recruiting
  • Hampton, VirginiaHospital not named in the registryNot yet recruiting
  • Huntsville, AlabamaHospital not named in the registryNot yet recruiting
  • Indianapolis, IndianaHospital not named in the registryNot yet recruiting
  • Jackson, MississippiHospital not named in the registryNot yet recruiting
  • Jacksonville, FloridaHospital not named in the registryNot yet recruiting
  • Kansas City, KansasHospital not named in the registryNot yet recruiting
  • La Mesa, CaliforniaHospital not named in the registryNot yet recruiting
  • Las Vegas, NevadaHospital not named in the registryNot yet recruiting
  • Leesburg, FloridaHospital not named in the registryNot yet recruiting
  • Little Rock, ArkansasHospital not named in the registryNot yet recruiting
  • Los Angeles, CaliforniaHospital not named in the registryNot yet recruiting
  • Melbourne, FloridaHospital not named in the registryContact: Ascletis RecruitingTaking people
  • Memphis, TennesseeHospital not named in the registryNot yet recruiting
  • Mesquite, TexasHospital not named in the registryNot yet recruiting
  • Morehead City, North CarolinaHospital not named in the registryNot yet recruiting
  • New Windsor, New YorkHospital not named in the registryNot yet recruiting
  • Olive Branch, MississippiHospital not named in the registryNot yet recruiting
  • Philadelphia, PennsylvaniaHospital not named in the registryNot yet recruiting
  • Phoenix, ArizonaHospital not named in the registryContact: Ascletis RecruitingTaking people
  • Raleigh, North CarolinaHospital not named in the registryNot yet recruiting
  • Rockville, MarylandHospital not named in the registryNot yet recruiting
  • Salt Lake City, UtahHospital not named in the registryNot yet recruiting
  • San Antonio, TexasHospital not named in the registryContact: Ascletis RecruitingTaking people
  • Schaumburg, IllinoisHospital not named in the registryNot yet recruiting
  • South Miami, FloridaHospital not named in the registryNot yet recruiting
  • St Louis, MissouriHospital not named in the registryNot yet recruiting
  • Sugar Land, TexasHospital not named in the registryNot yet recruiting
  • Tampa, FloridaHospital not named in the registryNot yet recruiting
  • Tarzana, CaliforniaHospital not named in the registryNot yet recruiting
  • The Villages, FloridaHospital not named in the registryContact: Ascletis RecruitingTaking people
  • Tomball, TexasHospital not named in the registryNot yet recruiting
  • Tucson, ArizonaHospital not named in the registryNot yet recruiting
  • Tustin, CaliforniaHospital not named in the registryNot yet recruiting
  • Union City, GeorgiaHospital not named in the registryNot yet recruiting
  • Valparaiso, IndianaHospital not named in the registryNot yet recruiting
  • Washington D.C., District of ColumbiaHospital not named in the registryNot yet recruiting
  • Weslaco, TexasHospital not named in the registryNot yet recruiting
  • Wichita Falls, TexasHospital not named in the registryNot yet recruiting
  • Winter Park, FloridaHospital not named in the registryNot yet recruiting

About the trial

What the trial wants to find out

Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight without T2DM.

The 4 groups in the trial

  • ASC30 Cohort 1Treatment being tested

    Participants will receive oral ASC30 tablets A1.

    Treatment: ASC30 tablets A1

  • ASC30 Cohort 2Treatment being tested

    Participants will receive oral ASC30 tablets A1.

    Treatment: ASC30 tablets A1

  • ASC30 Cohort 3Treatment being tested

    Participants will receive oral ASC30 tablets A1.

    Treatment: ASC30 tablets A1

  • Placebo Cohort 4Placebo, for comparison

    Participants will receive matching placebo tablets orally once daily.

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (AURORA-1)
Plain-language title
Daily ASC30 tablet for adults with obesity or overweightGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
16 September 2026